Skip to main content

Table 3 Base-case analysis

From: Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model

 

Results

Differences (Gains)

 

No vaccination (NV)

Quadrivalent (QV)

Bivalent (BV)

QV - NV

BV - NV

BV-QV

A: Health outcomes and disease-related costs

Undiscounted

 LYs

18,351,285

18,395,244

18,398,735

43,959

47,451

3,491

 QALYs

18,337,584

18,390,430

18,393,973

52,845

56,389

3,544

 Cervical cancer cases

7,398

2,967

2,616

−4,431

−4,781

−350

 Cervical cancer deaths

3,701

1,558

1,391

−2,143

−2,310

−168

 Genital Warts (new and recurrent)

21,025

2,566

21,025

−18,459

0

18,459

 Total cost other than vaccinationa

11,295.9 VEF

7,109.9 VEF

7,107.3 VEF

−4,186.0 VEF

−4,188.6 VEF

−2.6 VEF

  Costs of screening

4,323.0 VEF

4,396.1 VEF

4,383.3 VEF

73.1 VEF

60.3 VEF

−12.8 VEF

  Costs of CIN 1

601.4 VEF

303.3 VEF

344.9 VEF

−298.1 VEF

−256.5 VEF

41.5 VEF

  Costs of CIN 2/3

262.3 VEF

122.7 VEF

102.6 VEF

−139.6 VEF

−159.7 VEF

−20.1 VEF

  Costs of warts

309.2 VEF

37.7 VEF

309.3 VEF

−271.4 VEF

0.1 VEF

271.6 VEF

  Costs of cancer

5,800.1 VEF

2,250.1 VEF

1,967.3 VEF

−3,550.0 VEF

−3,832.7 VEF

−282.7 VEF

 Discounted (5%)

 LYs

5,277,952

5,281,034

5,281,282

3,082

3,330

248

 QALYs

5,276,066

5,280,461

5,280,552

4,395

4,486

91

 Total cost other than vaccinationa

2,435.2 VEF

1,602.7 VEF

1,672.5 VEF

−832.6 VEF

−762.8 VEF

69.8 VEF

  Costs of screening

1,130.3 VEF

1,151.9 VEF

1,148.5 VEF

21.6 VEF

18.2 VEF

−3.5 VEF

  Costs of CIN 1

167.1 VEF

82.8 VEF

91.8 VEF

−84.3 VEF

−75.4 VEF

9.0 VEF

  Costs of CIN 2/3

79.5 VEF

35.2 VEF

28.6 VEF

−44.3 VEF

−50.9 VEF

−6.6 VEF

  Costs of warts

136.7 VEF

16.7 VEF

136.7 VEF

−120.0 VEF

0.0 VEF

120.0 VEF

  Costs of cancer

921.6 VEF

316.0 VEF

266.9 VEF

−605.6 VEF

−654.7 VEF

−49.1 VEF

B: Vaccine costs per scenarioa

      

 2: Both vaccines = 8.5 US$; 2-dose scheme - FX 6.3

0 VEF

26.9 VEF

26.9 VEF

26.9 VEF

26.9 VEF

0 VEF

 4: Both vaccines = 8.5 US$; 2-dose scheme - FX: 170

0 VEF

726.2 VEF

726.2 VEF

726.2 VEF

726.2 VEF

0 VEF

 6: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX 6.3

0 VEF

43.7 VEF

26.9 VEF

43.7 VEF

26.9 VEF

−16.7 VEF

 8: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX: 170

0 VEF

1,178.1 VEF

726.2 VEF

1,178.1 VEF

726.2 VEF

−451.9 VEF

  1. Notes: A. Health outcomes and disease related costs (with and without discounting); B. Cost of vaccination (Scenarios 2, 4, 6 and 8)
  2. Abbreviations: NV no vaccination, QV quadrivalent, BV bivalent, FX foreign exchange rate (VEF per US$), CC cervical cancer. (See scenarios 1, 3, 5, 7 in Additional file 1: Table S2), VEF Venezuelan bolívar fuerte, QALYs quality-adjusted life years, LYs life-years, CIN cervical intraepithelial neoplasia, US$ United States dollar
  3. aCosts are expressed in millions of VEF, 2015